Opthea Limited ( ($AU:OPT) ) has shared an update. Opthea Limited has requested a voluntary suspension of its securities from trading on the ASX ...

This activity is supported by independent medical education grants from 4D Molecular Therapeutics; Alkeus Pharmaceuticals, Inc.; Genentech, a member of the Roche Group; Neurotech Pharmaceuticals ...

Trading in shares of Opthea is halted in the U.S. and Australia ahead of planned update by the clinical-stage biopharmaceutical company on a late-stage study of its lead product candidate ...

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...

The high-profile stockpicker is the eye disorder treatment hopeful’s biggest shareholder. Ahead of the results of a crucial ...

On St Patrick's Day, investors hope for the luck of the Irish ahead of Opthea's key trial update and Imricor's ambitious fund ...

Opthea Limited ( ($AU:OPT) ) has provided an update. Opthea Limited has requested a trading halt on its securities pending the announcement of the ...

We recently published a list of 10 Best Australian Stocks to Buy According to Billionaires. In this article, we are going to ...

ASX health stocks fell 0.43% over the past week, while the broader market 2.51% ProMedicus has signed a seven-year, $40 million deal with leading US radiology provider LucidHealth Opthea falls ...

Highlights,Opthea reports increased net loss for H1 2025,Significant revenue growth predicted over the next three years,Stock shows short-term decline of 18%,Opthea Ltd. (ASX:OPT) has disclosed its ...

Opthea Limited’s OPT share price has dipped by 11.56%, which has investors questioning if this is right time to buy.